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ABSTRACT
Introduction: Prostate cancer remains a health concern worldwide with an increasing global incidence. In Nigerian men it is the 
most common diagnosed cancer. Diagnosis of prostate cancer is made through biopsy and histology which in turn is 
dependent on prostate specific antigen and digital rectal examination finding.  
Objective: This study sought to look at the correlation between PSA , DRE and histology in patient who had prostate biopsy  
Method: It was a prospective study of all patients who presented to our clinic and had prostate biopsy. Data on age of patient, 
size of prostate,  PSA, DRE finding of benign or suspicious for cancer of the prostate and the final histology were collated and 
there correlation analysed using SPSS and Micros  Excel 2013.
Results: The mean age, prostate volume and PSA were 70.99+ 9.1years, 97.6+ 88.1ml and 70.13 + 73.2ng/ml respectively. The 
positive predictive value, negative predictive value and overall diagnostic accuracy are 55.61,  66.67, 55.77 respectively for PSA 
above 4ng/ml , 71.97, 73.68, 72.60 respectively for DRE alone and  55.59, 0.00, 55.29 respectively for a combination of PSA 
above 4ng/ml and DRE. 
Conclusion: PSA and DRE singly or in combination have a poor PPV  , NPV and ODA to help counseling of patients prior to prostate
biopsy.
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INTRODUCTION
rostate cancer remains a health 
Pc o n c e r n  w o r l d w i d e ,  w i t h  a n increasing global incidence.
It is the second most common cancer 
diagnosed among men and fth most 
common cause of cancer deaths among men, 
1,2
globally.  Among Nigerian men, it is the 
3,4most commonly diagnosed cancer.  While 
the true prevalence in Nigeria remains 
unknown, recent data suggest a hospital 
prevalence rate of 182.5 per 100,000 male 
admissions and 61.3 per 100,000 in the 
southwestern and southeastern Nigeria, 
5,6,7respectively. 
Despite being, mostly, a slow-growing 
cancer, thousands of men die of the disease 
each year. Thus, the need for early detection 
and intervention. Diagnosis is made through 
biopsy and histology. The main indications 
for biopsy are abnormal digital rectal 
examination (DRE) ndings and/or 
elevated serum Prostate-specic antigen 
8,9,10
(PSA) level. 
In Nigeria, DRE and serum PSA are mostly 
appl ied  in  the  course  of  assess ing 
individuals with clinical features suggestive 
11
of the disease.
Conicting reports abound, from several 
studies, with respect to positive predictive 
value, sensitivity and specicity of PSA and 
12-16 DRE. These indices were used to assess the 
efcacy of these screening tests.
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Variable N Range Minimum
 
Maximum Mean Std. Deviation 
Age 208 54.00   70.9856  
Prostate Volume 208 889.77   97.5937  











Table 1: Descriptive statistics of the age, prostate volume and total PSA. 
We aim to evaluate the efcacy of serum PSA 
and digital rectal examination in the 
diagnosis of prostate cancer in our locality 
METHOD
This was a 2 years prospective study of 
patients who underwent prostate biopsy in 
our centre. Inclusion criteria were all patient 
who had biochemical and/or clinical 
indication for prostate biopsy and consented 
to prostate biopsy.  The biochemical 
indications were patients with PSA above 
4ng/ml , while the clinical indications were 
ndings on DRE suspicious of cancer of the 
prostate as reported by a senior registrar in 
urology and/or a consultant urologist.
Patient  were counseled on the DRE 
procedure, placed on left lateral position, an 
index nger well lubricated with a water 
soluble gel is gently inserted into the rectum 
to assess the prostate and reported as benign 
or suspicious of malignancy. PSA was done 
By Elisa Method using Stat Fax-2100 
microplate reader of Awareness Technology 
Incooperated ,Ultrasound size of the prostate 
was done by radiologist using Aloka 
Prosound SSD 3500 and  histology of the 
prostate tissue was done by our pathologist 
using Haematoxylin and Eosin staining.  The 
ndings suspicious of cancer of the prostate 
included hard prostate, nodular prostate, 
xed rectal mucosa and/or palpable seminal 
vesicles. Ethical clearance was sought and 
received from the ethical committee of our 
institution. We also gave routine antibiotics 
in the form of Tablet ciprooxacin and 
metronidazole 1 hour  before the procedure 
and then for 5 days after biopsy. We routinely 
did a rectal washout on the morning of the 
procedure. 
On the day of the procedure, patients were 
placed in left lateral position with their hip 
and knees exed to 90 degree. In this position 
we scrubbed the lower back and buttocks. 
Using  20ml of 1% lignocaine we did a caudal 
block for the procedure.  Then with a plaster 
taped to the tip of our index nger (the nger 
that guides the biopsy needle to avoid injury 
to the operator) we did a Digitally guided 
prostate biopsy with size 18G semi-
R
automated Trucut  biopsy needle. We 
usually did a Sextant biopsy and biopsy of 
any palpable nodule or hardness.  After the 
biopsy we gave antibiotics as above and 
analgesics for 5days. 
We collected information on their biodata, 
PSA, Ultrasound size of the prostates, digital 
rectal examination nding and Histology 
results 
Analysis was done using statistical package 
for social sciences IBM SPSS Statistics for 
windows, version 21.0. Armonk, NY: IBM 
Corp. and Microsoft Excel 2013.
RESULTS
A total of 208 patients were qualied for the 
study. The mean age, prostate volume and 
PSA were 70.99+ 9.1years, 97.6+ 88.1ml and 
70.13 + 73.2ng/ml respectively (See table 1). 
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The positive predictive value, negative 
predictive value and overall diagnostic 
accuracy  is 55.61, 66.67, 55.77 respectively for 
PSA above 4ng/ml alone, 71.97, 73.68, 72.60 
respectively for DRE alone and  55.59, 0.00, 
55.29 respectively for a combination of PSA 
above 4ng/ml and DRE. 
Table 2 shows the various sensitivities, 
Table 2: Sensitivity, Specicity, PPV, NPV, and ODA of PSA and DRE
 Sensitivity Specicity  PPV NPV ODA 
PSA> 4ng/ml 99.13 2.15 55.61 66.67 55.77 
DRE 82.61 60.22 71.97 73.68 72.60 
PSA >4ng/ml± 
DRE 100 - 55.29 - 55.29 
PSA 10.1-20ng/ml 96.55 1.00 55.17 20 54.32 
PSA 20.1-50ng/ml 99.15 8.79 58.29 88.89 59.62 
PSA 50.1-100ng/ml 65.22 67.74 71.43 61.17 66.35 
PSA >100ng/ml 44.35 89.25 83.61 56.46 64.42 
DRE 82.61 60.22 71.97 73.68 72.60 
PSA 4-10ng/ml± 
DRE 100 0 55.29 - 55.29 
PSA 10.1-
20ng/ml±DRE 98.04 7.55 50.51 80 51.92 
PSA 20.1-
50ng/ml±DRE 94.78 24.73 60.89 79.31 63.46 
PSA 50.1-
100ng/ml±DRE 88.70 43.01 65.81 75.47 68.27 
PSA 
>100ng/ml±DRE 77.24 48.24 68.35 59.42 65.38 








Diagnos c parameters of DRE /& different PSA levels
Sensi vity Specificity PPV NPV ODA
specicities, positive predictive values 
(PPV), negative predictive values (NPV) 
and overall diagnostic accuracy (ODA) for 
various values of the PSA and DRE 
separately and in combination. The 
Diagnostic parameter of DRE and/or 
different PSA levels is depicted in gure 1
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DISCUSSION
Methods used to identify prostate cancer 
include DRE and PSA assay. The DRE, while 
being simple to perform, non-invasive and, 
17,18 relatively, inexpensive is subjective. Also 
as the entirety of the prostate is not assessed, 
up to 25% of prostate cancers detected with 
biopsy after abnormal DRE ndings are 
found in a different area than the palpable 
19abnormality.  Thus, DRE often detects 
17
advanced disease.
PSA is organ-specic but not cancer-specic 
and so other prostatic diseases, such as 
benign prostatic hyperplasia and prostatitis, 
may inuence its effectiveness for cancer 
20
detection.  However, it is objective and cost-
17effective.
All the patients in the present study had a 
transrectal digitally-guided needle biopsy of 
the prostate which was indicated by an 
abnormal DRE nding and/or abnormal 
serum PSA result. Diagnosis was by 
histology. Most of the serum PSA values 
were above 100ng/ml (29.3%) reecting the 
high incidence of late presentation in 
developing countries like ours where routine 
6,11screening is not being practised.  The PSA 
sensitivity in the present study was  99.13% at 
4ng/ml cut-off while DRE was 82.6%. This is 
21 similar to the ndings by De et al which 
showed sensitivity of 95% and 60% for PSA 
and DRE, respectively. A high sensitivity of 
94.6% for serum PSA was also observed by 
22
Ojewola et al  which outperformed DRE 
which had a sensitivity of 75.7%. Similar to 
23
our ndings, Cupp et al  noted sensitivity to 
be in the ranges of 57-79% and 69-89% for 
PSA and DRE, respectively following results 
from several studies.
The highest sensitivity of PSA in our study 
was noticed when PSA levels were 20.1-
50ng/ml with a value of 99.15%, in contrast to 
PSA levels of 0-3.9ng/ml with highest 
21
sensitivity of 95% noticed by De et al.  Their 
study population was 60 patients and their 
average total PSA was 12.09ng/ml while ours 
was 70.12ng/ml.
Combined, the sensitivity of DRE and PSA in 
our study was 100%.  This is similar to the 
20,21, 24ndings by other studies.  Several studies 
have actually, reported increasing sensitivity 
of PSA at lower cut-off values with resultant 
decreasing specicity. This is explainable by 
the fact that PSA is prostate-specic and not 
prostate-cancer-specic. In our study, PSA 
had a specicity of  2.15% at a cut-off value of 
4ng/ml while DRE was 60.22%. Lower 
values of 20.2% and 44.7% were found for 
22
PSA and DRE respectively, by Ojewola et al.  
20Abdrabo et al  inferred a similar specicity 
result for DRE (68%) which was far higher 
than the 24% noted for PSA in the same study.
In contrast to the observation by Abdrabo et 
20al , the combined specicity of PSA and DRE 
noted in our study was far less than the 
values for the individual PSA ranges. This is 
24similar to the ndings by Al Rumaihi et al 
The highest PSA specicity of 89.25%, in our 
study, was noticed at PSA values above 
100ng/ml. This is in keeping with the 99.7% 
25
observed by Lojanapiwat et al  where PSA 
levels above 100ng/ml were also noticed to 
be 90.7% specic for bone metastasis. 
The positive predictive value (PPV) of PSA, 
in our study, was noted to have progressively 
increased with increases in PSA levels. It was 
highest (83.61%) at PSA level above 
100ng/ml. Using 4ng/ml as PSA cut-off the 
value was 55.61%. Similar progressive 
25increase was noted by Lojanapiwat et al.
The PPV of DRE, in our study, was higher 
than that of PSA and was 71.97%. In contrast 
Similarly previous studies reported a higher 
12-14,26,27PPV for PSA than DRE.  This may be 
attributed to the late presentation as is 
6 , 1 1
c o m m o n  i n  o u r  e n v i r o n m e n t .   
Furthermore, we found that combined PPV 
of DRE and PSA was 55.29% which was less 
than the individual values of the two 
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parameters. This reects the report by De et 
21
al  but contrasts with several other studies 
where the combined values were higher than 
11-13,22,23 
the individual values. Thus, abnormal 
DRE in our environment  is more likely to be 
associated with cancer of the prostate in 
symptomatic patients and should guide 
counselling of patients before biopsy. 
However, as the PSA rises, the PPV increases 
and gets to 83.67% at PSA above 100ng/ml. 
The negative predictive value (NPV) of PSA 
at 4ng/ml in our study was  66.67% and that 
of DRE was 73.68%. In the work done by Al 
24 25
Rumaihi et al  and Lojanapiwat et al , they  
had NPV for PSA (above 4ng/ml) of 78.4% 
and 87.5% respectively which is higher than 
that recorded in our study. A progressively, 
decreasing NPV with increasing PSA was 
25
noticed by Lojanapiwat et al , similar to our 
own nding.
Outside PSA levels between 20.1-50ng/ml, in 
our study, DRE increased the NPV in all other 
PSA ranges. However, the low combined 
NPV (Zero percent) of DRE and PSA at 
4ng/ml cut off in our study showed that the 
two parameters cannot be relied on to 
exclude the presence of Ca prostate in pre- 
biopsy patients.
The diagnostic accuracy of a test relates to the 
ability of the test to discriminate between the 
target condition and health. We found that to 
be 72.60% for DRE and 55.77% for PSA at a 
cut-off of 4ng/ml. the higher value for DRE 
is, possibly, due to the fact that our study 
population comprised, mainly, of referred 
patients and not unscreened population.
Similar higher detection accuracy of DRE was 
22noticed by Ojewola et al  in their study with 
values of 58% and 53% for DRE and PSA, 
respectively. The detection accuracy of PSA, 
progressively, improved with rising PSA 
levels, and with similar improvements when 
PSA levels >20ng/ml were considered with 
abnormal DRE.
A comparable detection accuracy of 79.9% for 
28
DRE was observed by Akdas et al  which 
improved to 84.2% when combined with PSA 
and trans-rectal ultrasound. 
Our study showed that neither DRE or PSA 
had sensitivity or specicity, enough to be of 
high diagnostic value.
Though combined, the sensitivity of both 
rose to 100%, but the reverse was observed 
with their specicity.
The diagnostic accuracy of PSA was noticed 
to be progressively increasing with 
increasing PSA levels and, further still, when 
DRE was combined with PSA above 
20ng/ml. DRE had a, relatively, high 
detection accuracy in our study.
The efcacy of these screening tools in the 
diagnosis of prostate cancer is higher when 
both tools are applied and will increase 
fur ther  i f  t ransrecta l  u l t rasound is 
29,30employed.  
CONCLUSION
In conclusion, PSA and DRE singly or in 
combination have a poor PPV, NPV and 
ODA to help counseling of patients prior to 
prostate biopsy. However, on a scale of 
preference in our environment DRE with an 
overall diagnostic accuracy of 72.6% is better 
in predicting the diagnosis of carcinoma of 
the prostate than PSA with an overall 
diagnostic accuracy of 55.77%.
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